Figure 5.

Metabolic alterations in samples with 17p-. 17p- (n = 42) and control (non-17p-; n = 19) CLL cells were cultured for 48 hours and the residual concentration of glucose (A) and lactate (B) in the media was assessed. (C) There was a correlation between the spontaneous glucose consumption and lactate production in CLL cells (data from (A) and (B)). CLL cells with the highest glucose consumption (n = 12) are highlighted in colors and respresented as a distinct group “good glucose consumers” in (D). (E) Representative immunoblots of 17p- and control cells show strongly increased expression of HK2, PFKFB3, and LDHA in 17p- cases, particularly in the samples with highest glucose consumption. (F) The respiratory reserve of CLL cells was assessed by treating CLL cells with FCCP and measuring their oxygen consumption. 17p- CLL (n = 13) cells had significantly higher respiratory capacity than non-17p- CLL cells (n = 4). (G–J) 17p-CLL cells were treated with 1µM ibrutinib (or vehicle control—DMSO) for 48 hours in the unstimulated (G, H; n = 8) or anti-IgM stimulated (I, J; n = 9) condition and the spent media was assessed for the residual glucose (G, I) and lactate levels (H, J). CLL = chronic lymphocytic leukemia.